Trial Profile
GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms GASTRICHIP
- 02 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2020 Planned End Date changed from 1 May 2025 to 1 May 2026.
- 02 Dec 2020 Planned primary completion date changed from 1 May 2025 to 1 May 2026.